CGTX
Cognition Therapeutics Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Cognition Therapeutics Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Cognition Therapeutics has 9 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceWe are conducting the START clinical trial in collaboration with the Alzheimer's Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias.
CGTX 10-Kaccession 0001104659-26-034880
SentenceCognition has received and is reviewing scientific advice from the European Medicines Agency (EMA) indicating a preference for a longer trial than was proposed.
CGTX 10-Kaccession 0001104659-26-034880
SentenceOn March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") for an equity line financing (the "Lincoln Park Purchase Agreement").
CGTX 10-Kaccession 0001104659-26-034880
SentenceIn work funded by grants from the Michael J. Fox Foundation, α-synuclein oligomers were found to bind to brain cells in culture and are internalized as indicated by the red dots in the image to the left below.
CGTX 10-Kaccession 0001104659-26-034880
SentenceOur clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA.
CGTX 10-Kaccession 0001104659-26-034880
SentenceOur clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA.
CGTX 10-Kaccession 0001104659-26-034880
SentenceTo date, we have partially relied on the availability of NIA Grants.
CGTX 10-Kaccession 0001104659-26-034880
SentenceZervimesine has continued to be generally well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, for AD.
CGTX 10-Kaccession 0001104659-26-034880
SentenceThe United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024.
CGTX 10-Kaccession 0001104659-26-034880
SentenceThe Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park to purchase up to $35.0 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023.
CGTX 10-Kaccession 0001104659-26-034880
Cognition Therapeutics Inc
0.69
Largest filed tie
—
Expected move
No implied move.